1. Medication and aggressiveness in real-world schizophrenia. Results from the FACE-SZ dataset
- Author
-
Mathieu Urbach, Isabelle Chereau, Dubreucq, Guillaume Fond, Lore Brunel, Bruno Aouizerate, P. Vidalhet, M. Favez, David Misdrahi, Christine Passerieux, Romain Rey, A. Schandrin, L. Boyer, C. Lançon, Delphine Capdevielle, A.M. Tronche, Fabrice Berna, H. Laouamri, Antoine Pelissolo, F. Schürhoff, Y. Le Strat, Jean-Michel Dorey, F. Gabayet, Pierre-Michel Llorca, Catherine Faget, Caroline Dubertret, Fondation FondaMental [Créteil], Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Neuro-Psycho Pharmacologie des Systèmes Dopimanégiques sous-corticaux (NPsy-Sydo), CHU Clermont-Ferrand-Université Clermont Auvergne [2017-2020] (UCA [2017-2020]), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Neuropsychologie Cognitive et Physiopathologie de la Schizophrénie (NCPS), Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Civil de Strasbourg, and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
- Subjects
medicine.medical_specialty ,Cross-sectional study ,medicine.medical_treatment ,Schizoaffective disorder ,Violence ,Antipsychotic ,03 medical and health sciences ,Aggressiveness ,0302 clinical medicine ,medicine ,Young adult ,Psychiatry ,Pharmacology ,Benzodiazepine ,biology ,Buss perry scale ,[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences ,medicine.disease ,biology.organism_classification ,3. Good health ,030227 psychiatry ,Mood ,Schizophrenia ,[SDV.MHEP.PSM]Life Sciences [q-bio]/Human health and pathology/Psychiatrics and mental health ,[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] ,Cannabis ,Psychology ,030217 neurology & neurosurgery ,Clinical psychology ,Cohort study - Abstract
International audience; INTRODUCTION:The primary objective of this study was to determine if second-generation antipsychotic (SGA) administration was associated with lower aggressiveness scores compared to first-generation (FGA) in schizophrenia (SZ). The secondary objective was to determine if antidepressants, mood stabilizers, and benzodiazepines administration were respectively associated with lower aggressiveness scores compared to patients who were not administered these medications.METHODS:Three hundred thirty-one patients with schizophrenia (N = 255) or schizoaffective disorder (N = 76) (mean age = 32.5 years, 75.5 % male gender) were systematically included in the network of FondaMental Expert Center for Schizophrenia and assessed with the structured clinical interview for DSM-IV Axis I disorders and validated scales for psychotic symptomatology, insight, and compliance. Aggressiveness was measured by the Buss-Perry Aggression Questionnaire (BPAQ) score. Ongoing psychotropic treatment was recorded.RESULTS:Patients who received SGA had lower BPAQ scores than patients who did not (p = 0.01). More specifically, these patients had lower physical and verbal aggression scores. On the contrary, patients who received benzodiazepines had higher BPAQ scores than patients who did not (p = 0.04). No significant difference was found between BPAQ scores of patients respectively being administered mood stabilizers (including valproate), antidepressant, and the patients who were not. These results were found independently of socio-demographical variables, psychotic symptomatology, insight, compliance into treatment, daily-administered antipsychotic dose, the way of antipsychotic administration (oral vs long acting), current alcohol disorder, and daily cannabis consumption.CONCLUSION:The results of the present study are in favor of the choice of SGA in SZ patients with aggressiveness, but these results need further investigation in longitudinal studies. Given the potent side effects of benzodiazepines (especially dependency and cognitive impairment) and the results of the present study, their long-term prescription is not recommended in patients with schizophrenia and aggressive behavior.
- Published
- 2015